Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduced Ejection Fraction
Shots:
- The NICE has issued its final draft guidance recommending Jardiance (empagliflozin) as an option for the treatment of symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults
- The recommendation was based on the P-III (EMPEROR-Preserved) trial results evaluating Jardiance which demonstrated that empagliflozin achieved its primary composite EPs (CV death or hospitalization for HF) in adults with an ejection fraction of ≥40%
- The NICE earlier advised empagliflozin in Mar 2022 for symptomatic chronic heart failure in patients with low ejection fraction. This recommendation will increase the usage of empagliflozin
Ref: Pharmaweb | Image: Boehringer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
